Marine pharmacognosy Compounds from Marine Sources in Clinical Level Clinical Pipeline of Marine Pharmacology, July 2011. From http://marinepharmacology.midwestern.edu/clinPipeline.htm

| Clinical_Status | Compound_Name | Trademark | Marine_Organism_α | Chemical_Class | Molecular_Target | Clinical_Trials_β | Disease_Area |
|---|---|---|---|---|---|---|---|
| Phase I | SGN-75 | N/A | Mollusk | Antibody Drug Conjugate (MM Auristatin F) | CD70 and Microtubules | 2/2 | Cancer |
| Phase I | ASG-5ME | N/A | Mollusk | Antibody Drug Conjugate (MM auristatin E) | ASG-5 and Microtubules | 2/2 | Cancer |
| Phase I | Hemiasterlin (E7974) | N/A | Sponge | Tripeptide | Microtubules | 0/3 | Cancer |
| Phase I | Bryostatin 1 | N/A | Bryozoa | Polyketide | Protein Kinase C | 0/38 | Cancer, Alzheimers |